Following the national introduction of the rotavirus vaccine in Kenya, our impact evaluation across two surveillance sites indicates a substantial reduction in childhood hospitalisation due to rotavirus-associated and all-cause severe diarrhoea.
Introduction
Rotavirus is a major contributor to severe diarrhoea illness and related mortality, especially in low and middle income countries [1] [2] [3] . Global estimates suggest that in 2013, rotavirus accounted for 215000 or 3.4% of all deaths in children aged <5 years [4] .
In 2009, the World Health Organisation (WHO) recommended that all countries, especially those with high diarrhoea associated child mortality rates, implement rotavirus immunisation programmes [5] . Kenya adopted this recommendation in July 2014 [6, 7] . Since then, two doses of live attenuated rotavirus vaccine (Rotarix TM ), in addition to oral polio, pneumococcal conjugate (PCV) and pentavalent vaccines, have been recommended to children in Kenya, targeted at 6 and 10 weeks of life, as part of the routine child immunisation programme [8, 9] . It was estimated that introduction of this vaccine in Kenya would avert over 60,000 deaths and over 200,000 hospitalisations among children aged <5 years during the first 20 years of introduction [10] . Following vaccine introduction, we used demographic and hospital data from two populationbased surveillance sites in Kenya to estimate the impact of the programme on rotavirus hospitalizations in children <5 years.
Methods

Geographical Location
The study was conducted in two regions with established demographic surveillance systems (DSS): the Kilifi Health and Demographic Surveillance System [11] 
Vaccine introduction and coverage
Rotavirus vaccine was introduced into the childhood vaccination programme in both Kilifi and Siaya counties in July 2014. Children who were aged 6 weeks or younger or born after the start of the rotavirus immunisation programme were eligible to receive one dose at 6 weeks and one dose at 10 weeks, though vaccine stock outs in November [12] . In addition, the vaccination status of children enrolled in the rotavirus surveillance at Siaya County Referral Hospital is recorded at the time of hospital admission. In both sites, card confirmed vaccine information was captured by the field staff
Rotavirus surveillance
In 2009, to prepare for vaccine introduction [12, 14] , rotavirus surveillance was intensified at Siaya County Referral Hospital among children aged < 5 years who presented with three or more loose stools within a 24-hour period and one or more vomiting episodes. In Kilifi, rotavirus surveillance was initiated in late 2009 in inpatient children aged less than 13 years with three or more loose stools within a 24hour period. Parents of eligible children were briefed on the potential risks and benefits before of the study before being asked to give consent by the study team. Stool samples were collected from eligible children, whose parents provided voluntary 6 informed consent, and tested for rotavirus antigen by Enzyme-Linked Immunosorbent Assay (ELISA), as described previously [14, 15] .
Surveillance was interrupted by 12 industrial actions (strikes), including 7 before and 5 after rotavirus vaccine introduction, by different cadres of health care workers as indicated in supplementary Table1. For the analysis of rotavirus positive diarrhea, a sensitivity analysis was conducted using a synthetic control [17] [18] [19] in the regression model instead of rotavirus negative cases. The synthetic control was generated by weighting three conditions (rotavirus 7 negative diarrhoea, pneumonia, malaria)-using SYNTH [20] command in Stata-so that their sum closely resembled the pre-vaccine rotavirus positive time series.
Statistical analysis
All statistical analyses were conducted using Stata13.1 software, (Stata Corporation, College Station, TX, USA). All datasets, Stata files and related documentation are available on an online data repository (https://doi.org/10.7910/DVN/PH4COG ) [21] .
Ethics Review
Ethical approval to conduct this study was granted by the KEMRI Scientific and Ethics Review Unit (SERU) (SSC # 3049) and the CDC's institutional review board (protocol #6968).
Results
Incidence and Seasonality
During the study period, there were 1513 and 1652 diarrhoea hospitalisations in Kilifi County Hospital and Siaya County Referral Hospital, respectively. In Kilifi, 1142 (75.5%) of the diarrhoea cases were tested and among those tested 315 (27.6%) were positive for rotavirus. In Siaya, 877 (53.1%) were tested and 197 (22.5%) were positive for rotavirus.
The proportion of children living in the study areas who received rotavirus vaccine increased with time. Between 2014 (year of introduction) and 2017, the proportion of aged <1 year with at least one dose increased from 31% to 73% in Kilifi and 16% to 75% in Siaya; the proportion fully vaccinated (two doses) in 2017 was 65% in Kilifi and 62% in Siaya. The highest coverage among infants was observed in 2016. Among children aged 12-23 months, the proportion with at least one dose increased from 0% to 86% in Kilifi and 0% to 94% in Siaya; coverage with two doses in 2017 was 84% and 92% repectively (Figure 1) . The lowest proportions of vaccinated children were observed in 2014 across both sites due to vaccine roll-out in mid-year and the unexpected stock-out. Among vaccinated children, the median age at receipt of the first dose was 6 weeks (interquartile range [IQR] 6 to 7) in Kilifi and 6 weeks (IQR: 6 to 7) in Siaya; median at age receipt of the second dose was 10 weeks (IQR 10 to 13) in Kilifi and 10 weeks (IQR 10 to 12) in Siaya.
Across the two demographic surveillance systems, overall diarrhoeal illness and rotavirus-specific illness displayed seasonal patterns which were dampened after the introduction of the vaccine (Figure 2 ). Siaya generally recorded higher diarrhoea and rotavirus associated diarrohoea incidences compared to Kilifi in the pre-vaccination era ( Tables 1 and 2 ). In Kilifi, the highest numbers of rotavirus cases were recorded from April/May to September/November of the same year (Figure 2a ). In Siaya, the RVH season began earlier in the year, usually in January /February (Figure 2b) . At both sites, there was a declining trend in annual incidence of diarrhoea and RVH that began prior to the rotavirus immunization programme and continued following introduction of vaccine (2015-2017). During the years affected by industrial actions of health workers (Supplementary Table1) lower rotavirus incidence rates were recorded at both sites ( Table 2) .
Impact of vaccine using rotavirus negative control series
In Kilifi, we observed reduced rates of RVH among KHDSS resident children <5 years throughout the post vaccination period ( Table 3 and Figure 3 ). When compared with rates from the pre-vaccine era, reductions were observed during the first year (57%, 95% CI: 8.0-80.0), the second year (80%, 95% CI: 46-93) and third year (76%, 95% CI: 56-87) ( Supplementary Figure 3(a) ). Similarly, in Siaya there were reductions in the first year (59%, 95% CI: 20-79), second year (82%, 95% CI: 61-92) and third year (81%, 95% CI: 7-96) post vaccine introduction ( Supplementary Figure 3(b) ).
Impact of vaccine on all-cause diarrhoea
When examining trends in all-cause diarrhoea using non-diarrhoea hosptializations as the control series, significant reductions were observed at both sites in post-vaccine introduction years (Table 3) , though by a smaller magnitude compared to reductions in RVH. In Kilifi, impact of the vaccine on all-cause diarrhoea increased from 41% (95% CI: 16 to 59) in the first year to 48% (95% CI: 40 to 55) and 46% (95% CI: 34 to 55) in the second and third year respectively ( Supplementary Figure 3(e) ). In Siaya, there was a 41% (95% CI: 27 to 52) reduction of all cause diarrhoea in the first year followed by 60% (95%CI: 43 to 72) in the second year and and 62% (95% CI: 38 to 77) reduction in the third year ( Supplementary Figure 3(f) ).
Impact of the vaccine on RVH using synthetic controls
The associated weights for each component of the synthetic control are shown in Supplementary Table 2, and the results of vaccine impact analysis in Supplementary   Table 3 and Supplementary Figure 3 . Vaccine impact estimates from this analysis are similar to those presented in Table 3 , except that estimate for the last year in Kilifi was slightly lower than the corresponding estimate in Table 3 . In Kilifi, impact of the vaccine was 67% (95% CI: 27 to 85) in the first year, 86% (95% CI: 64 to 94%) in the second year and 69% (95% CI: 45 to 83) in the third year. Similarly, in Siaya vaccine impact increased from 68% (95% CI: 33 to 84) in the first year to 89% (95% CI: 68 to 96) in the second year and 82% (95% CI: 8 to 96%) in the third year.
Discussion
We present results of an evaluation of the impact of rotavirus vaccine in Kenya using data from two population-based surveillance systems. Kenya introduced Rotarix TM vaccine into the national programme as a 2 dose schedule (6 and 10 weeks of age). We observed that most vaccinated children at both sites received either one or both doses of the vaccine within 3 weeks of the recommended time of vaccination. We estimate impact of the vaccine on RVH using non rotavirus hospitalisations and synthetic controls to control for any secular trends unrelated to the vaccine. Despite differences in the incidence of rotavirus disease in Kilifi and Siaya, as observed in this study and previous studies [15, 22] , the impact of vaccination was similar at both sites. In the first year post vaccine introduction, RVH declined by close to 60% in both Kilifi and Siaya, and all-cause diarrhoea declined by over 40% at both sites. In the second year of vaccination RVH further declined to over 80%, and this decline was sustained into the third post-vaccine introduction year with increasing coverage. Similarly, the positive impact of the vaccine on all-cause diarrhoea increased in the second and third years to as high as 60% reduction thus providing clear evidence of the substantial public health value of rotavirus immunization. These reductions suggest that vaccination of children aged less than two years, who are most likely to transmit rotavirus, optimizes direct and indirect protection against severe diarrhoeal infections.
Our estimates of rotavirus vaccine impact in the first year of vaccination are consistent with estimates from other African studies, which have ranged between 54% and 61% reduction for RVH and between 43% and 48% for all-cause diarrhoea hospitalizations [23, 24] . The same studies reported increasing impact in the second year of vaccination as was observed in our study.
Using the average of the 2013's Kilifi and Siaya rotavirus disease incidence estimates (166 per 100,000 per year) to represent disease incidence in Kenya in the absence of rotavirus vaccination, and assuming an under 5 population size of 6 million [25] , an 80% vaccine impact equates to approximately 8,000 rotavirus-related hospitalisations prevented per year in Kenyan children <5 years. Over 20 years this corresponds to 160,000 hospitalisations prevented, which is similar to a previous estimate of 200,000 [10] .
Our study was impacted by health worker industrial actions and a pre-vaccine secular trend in RVH, possibly reflecting improved sanitation and hygiene [26] . To mitigate against these potential sources of bias we included the monthly rotavirus negative (or synthetic control) as an offset term in our regression model. Additionally, we excluded the longest strike period (July-December 2017) from our analysis. An important assumption of this analysis is that the rotavirus negative count reflects the counterfactual trend in rotavirus positive cases that would have been observed in the absence of vaccination. Another limitation we considered was that only a fraction (75% in Kilifi and 53% in siaya) of eligible diarrhoea cases were tested for rotavirus which represents another potential source of bias. To adjust for this, we imputed the number of rotavirus cases by multiplying the number of diarrhoea cases by the fraction that tested positive. This imputation assumes that the fraction rotaviruspositive is the same in those tested as it is in those who were not tested, and may itself introduce bias, particularly if the fraction tested changes over time.
In conclusion, results from this study suggest that the burden of rotavirus and all- Table 1 : Monthly diarrhoea and rotavirus counts and incidence rates per 100,000 children per year by site prior to rotavirus vaccine introduction (January 2010 -June 2014). Rotavirus incidence rates are scaled as described in methods. 
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